Choosing the right stent for patients with ST-segment elevation myocardial infarction: the evidence-based approach.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy

• Publication date

  2016-03-02

• Fields of study

  Medicine

• Identifiers
  PMID 26934658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.

  2016cited by this paper
• Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.

  2016cited by this paper
• Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.

  2016cited by this paper
• Optical coherence tomography: guided primary percutaneous coronary intervention in acute myocardial infarction. A bridge too far?

  2015cited by this paper
• Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary ste

  2015cited by this paper
• Complete infarct-related artery revascularization in acute myocardial infarction patients. CORAMI Registry

  2015cited by this paper
• Direct stenting versus pre-dilation in ST-elevation myocardial infarction: a systematic review and meta-analysis.

  2015cited by this paper
• Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.

  2015cited by this paper
• Long-term use of ticagrelor in patients with prior myocardial infarction.

  2015cited by this paper
• Temporal trends and patterns in percutaneous treatment of coronary artery disease in Poland in the years 2005-2011.

  2015cited by this paper
• Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction: Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial

  2015cited by this paper
• Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.

  2015cited by this paper
• Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls

  2015cited by this paper
• Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial

  2015cited by this paper
• Stent selection and antiplatelet therapy duration: one size does not fit all.

  2015cited by this paper
• Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users

  2015cited by this paper
• Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I.

  2015cited by this paper
• Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.

  2015cited by this paper
• A prospective, postmarket study with the Mguard Prime Embolic Protection Stent in ST‐segment elevation myocardial infarction: The International MGuard Prime Observational Study (IMOS Prime)

  2015cited by this paper
• Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

  2015cited by this paper
• What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction?

  2015cited by this paper
• Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.

  2015cited by this paper
• Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?

  2015cited by this paper
• Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

  2015cited by this paper
• Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial.

  2015cited by this paper
• A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.

  2015cited by this paper
• Bioresorbable vascular scaffolds in saphenous vein grafts (data from OCTOPUS registry)

  2015cited by this paper
• Percutaneous interventions in cardiology in Poland in the year 2014. Summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society AISN PTK

  2015cited by this paper
• Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial).

  2015cited by this paper
• Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.

  2015cited by this paper
• Intracoronary adenosine administered during aortocoronary vein graft interventions may reduce the incidence of no-reflow phenomenon. A pilot randomised trial.

  2014cited by this paper
• Impact of direct stenting on outcome of patients with ST‐elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry)

  2014cited by this paper
• Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted Fro

  2014cited by this paper
• Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives

  2014cited by this paper
• Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial).

  2014cited by this paper
• Early stent thrombosis. Aetiology, treatment, and prognosis

  2014cited by this paper
• Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’

  2014cited by this paper
• Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction: Two-Year Clinical Results of the COMFORTABLE AMI Trial

  2014cited by this paper
• Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.

  2014cited by this paper
• Treatment of left main coronary artery stenosis with the STENTYS self-expandable drug-eluting stent – a pilot registry

  2014cited by this paper
• Drug-eluting stents compared to bare-metal stents improve short-term survival in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a nationwide prospective analysis of the AMIS Plus registry.

  2014cited by this paper
• TASTE-less endpoint of 30-day mortality (and some other issues with TASTE) in evaluating the effectiveness of thrombus aspiration in STEMI: not the "evidence" to change the current practice of routine consideration of manual thrombus extraction.

  2014cited by this paper
• Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry.

  2014cited by this paper
• Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes.

  2014cited by this paper
• Patients with atrial fibrillation undergoing percutaneous coronary intervention: current concepts and concerns: part II.

  2014cited by this paper
• Borderline trend towards long‐term mortality benefit from drug eluting stents implantation in ST‐elevation myocardial infarction patients in Poland—data from NRDES registry

  2014cited by this paper
• Stent selection to minimize the risk of stent thrombosis

  2014cited by this paper
• Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study.

  2014cited by this paper
• “Leaving nothing behind”: is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease?

  2014cited by this paper
• Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction.

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca

  2014cited by this paper
• Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials.

  2013cited by this paper
• Time course, predictors and clinical implications of stent thrombosis following primary angioplasty

  2013cited by this paper
• MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration.

  2013cited by this paper
• Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program

  2013cited by this paper
• The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.

  2013cited by this paper
• A meta-analytic overview of thrombectomy during primary angioplasty.

  2013cited by this paper
• Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty

  2013cited by this paper
• Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

  2012cited by this paper
• Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.

  2012cited by this paper
• Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial.

  2012cited by this paper
• Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.

  2012cited by this paper
• Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction.

  2012cited by this paper
• Advantages of MGuard coronary stent system.

  2012cited by this paper
• Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.

  2012cited by this paper
• Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.

  2012cited by this paper
• Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction.

  2012cited by this paper
• A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.

  2012cited by this paper
• Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial.

  2012cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

  2012cited by this paper
• Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials.

  2011cited by this paper
• Comparison of direct stenting with conventional stent implantation in acute myocardial infarction.

  2011cited by this paper
• Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry

  2011cited by this paper
• Assessment of the safety and performance of the STENTYS self-expanding coronary stent in acute myocardial infarction: results from the APPOSITION I study.

  2011cited by this paper
• Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

  2011cited by this paper
• A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.

  2010cited by this paper
• Multicentre experience with MGuard™ net protective stent in ST‐elevation myocardial infarction: Safety, feasibility, and impact on myocardial reperfusion

  2010cited by this paper
• Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

  2010cited by this paper
• Mesh covered stent in ST-segment elevation myocardial infarction.

  2010cited by this paper
• Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.

  2009cited by this paper
• Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study).

  2009cited by this paper
• The risk of definitive stent thrombosis is increased after “off-label” stent implantation irrespective of drug-eluting stent or bare-metal stent use

  2009cited by this paper
• A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score

  2009cited by this paper
• Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction.

  2008cited by this paper
• Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials.

  2008cited by this paper
• Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction.

  2007cited by this paper
• Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.

  2007cited by this paper
• Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade

  2003cited by this paper
• Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction.

  2002cited by this paper
• A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction.

  2002cited by this paper
• Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

  2002cited by this paper
• Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction.

  2002cited by this paper

• An interesting case of a self-apposing stent implantation in an aneurysmatically dilated artery in acute myocardial infarction with high quality optical coherence tomography images

  2017cites this paper